Department of Psychiatry
Penn Behavioral Health

Center for Studies of Addiction

subpage feature

Addiction Treatment and Medication Development Division

Clinical Trials


The Addiction Treatment and Medication Development Division is conducting a number of clinical trials that are on-going or soon to begin.

If you are interested in getting more information about any of these studies, please call 215-243-9959.




ALCOHOL TREATMENT STUDIES

Study Name: A Phase II, Double Blind, Placebo-Controlled Trial to Assess the Efficacy of ABT-436 for Alcohol Dependence (ABT)
Diagnosis: Alcohol Dependence
Age:  21-65
Study Involves: Alternating phone and office visits for medical management (MM), to assess drug compliance and to provide drug counseling (via “Take Control” videos)  
Duration: 13 weeks plus phone follow-up
Study Status: Active – no longer recruiting participants


 




COCAINE TREATMENT STUDIES

Study Name: Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence: A Phase III, Randomized, Double-Blind Trial of Adderall-XR and Topiramate (TACT)
Diagnosis or Problem: Cocaine Dependence
Age: 18-60
Study involves: Three visits weekly that include medical management (MM) and a supportive behavioral treatment to enhance adherence to the study drug
Duration: 15 weeks plus follow up visit
Study Status: Active – recruiting participants

 

Study Name: A Phase II Randomized, Double-blind, Placebo-Controlled,  Trial of Varenicline (Chantix™) for the Treatment of Cocaine Dependence (Chantix Cocaine 2)
Diagnosis or Problem: Cocaine Dependence
Age: 18-65
Study involves: Three visits weekly for the purposes of medical management (MM), cognitive behavioral therapy (CBT), to complete questionnaires and assess drug compliance
Duration: 12 weeks
Study Status: Active – recruiting participants


Study Name
:  Genetics of Cocaine Dependence
Diagnosis or Problem: Cocaine Dependence or Control Participants (persons with no history of substance abuse or psychiatric problems) 
Age:  18 years and up
Study Involves: Subjects' participation in the study will consist of one visit during which informed consent will be obtained, research assessments will be collected, and a blood sample will be drawn. This study does not provide treatment directly. 
Duration: 1 visit
Study Status: Active - recruiting participants

 


OPIOID TREATMENT STUDIES

Study Name A Randomized, Double-Blind, Double-Dummy, Active-Controlled Multicenter Study of Adult Outpatients with Opioid Dependence Transitioned from a Daily Maintenance Dose of 8 mg or Less of Sublingual Buprenorphine or Buprenorphine/Naloxone to Four Probuphine® Subdermal Implants (PRO-814)
Diagnosis or Problem: Opioid Dependence
Age:  18-65 years of age
Study Involves: Up to 28 weeks, including screening (up to 2 weeks), maintenance/active study drug treatment (24 weeks), and follow-up (2 weeks).
Duration: 28 weeks
Study Status: Active - recruiting participants

 

 

 

 

 

 

 

 





 

 


 



 

< back to Addiction Treatment main page